Welcome to our dedicated page for Hoth Therapeutics news (Ticker: HOTH), a resource for investors and traders seeking the latest updates and insights on Hoth Therapeutics stock.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) is a clinical-stage biopharmaceutical company whose news flow is centered on the development of therapies for oncology, dermatology, neurodegenerative disease, metabolic disease, and inflammatory conditions. Company updates frequently highlight progress across its pipeline, including HT-001 for cancer-therapy–related skin toxicities, HT-KIT for KIT-driven cancers and mast-cell diseases, HT-ALZ for Alzheimer’s disease, and a GDNF-based metabolic program targeting obesity and fatty liver disease.
News releases from Hoth often cover clinical milestones such as Phase 2 trial activity for HT-001 in EGFR-inhibitor–associated rash, first-in-human study preparations, and regulatory developments in the European Union and the United States. The company also reports on FDA designations, including Orphan Drug Designation for HT-KIT, and on IND-enabling progress and preclinical data in systemic mastocytosis and GIST models.
Investors and followers of HOTH stock can also expect updates on intellectual property expansion, including provisional patent filings and international patent protection related to HT-001 and other programs. Hoth regularly announces collaborations and research partnerships, such as its VA-backed GDNF study at the Atlanta VA Medical Center and participation in NVIDIA’s AI-focused programs to support computational biology and predictive modeling.
This news page aggregates Hoth Therapeutics’ press releases and related coverage, providing a single place to review developments in its clinical trials, regulatory interactions, AI-enabled research initiatives, conference presentations, and corporate communications. Readers interested in the evolution of HOTH’s pipeline and regulatory strategy can use this feed to monitor ongoing announcements and historical updates.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) has signed a Letter of Intent to merge with Algorithm Sciences, Inc., which specializes in treatments for Pulmonary Arterial Hypertension (PAH). The merger aims to amplify Hoth's market potential, with an anticipated combined valuation yielding billions in market opportunities for shareholders. Post-merger, Algorithm shareholders will hold approximately 86% of the new entity. The leadership team will include former AstraZeneca executive Anthony Zook as Chairman and Mike Tilton as CEO. The PAH treatment market is projected to grow from $7.2 billion in 2021 to $12 billion by 2031, a CAGR of 5.2%. The transaction completion is subject to regulatory reviews and stockholder approval.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced the activation of Washington University School of Medicine in St. Louis as the first clinical site for the CLEER-001 Phase 2a clinical trial of HT-001. This trial targets rash and skin disorders associated with epidermal growth factor receptor (EGFR) inhibitor therapy, which is significant for cancer patients undergoing treatment for various cancers, including non-small cell lung cancer and breast cancer. CEO Robb Knie emphasized the importance of this milestone in improving patient quality of life.
On February 16, 2023, Hoth Therapeutics (NASDAQ:HOTH) announced a partnership with Shareholder Intelligence Services to investigate illegal naked short selling activities of its stock. This collaboration aims to enhance monitoring of trading activities, including broker-dealer positions and shareholder movements. CEO Robb Knie stated that this initiative will help identify suspicious trading and protect investor interests. The patented process used by ShareIntel will allow Hoth to proactively track ownership and correct any trading anomalies, reinforcing the company's commitment to safeguarding shareholder interests.
Hoth Therapeutics, Inc. (NASDAQ:HOTH) has reported promising proof-of-concept data for its Alzheimer's disease therapeutic, HT-ALZ, following a study on aged APP/PS1+/- mice. Using doses of 20mg/kg and 40mg/kg, results indicated significant cognitive improvements, including reduced anxiety levels and enhanced spatial memory performance in maze tests. The research, conducted with Washington University in St. Louis, highlights HT-ALZ's potential under the 505(b)(2) regulatory pathway. Previous studies also demonstrated a notable decrease in brain amyloid β levels after acute treatment with HT-ALZ.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) has initiated patient recruitment for its Phase 2a clinical trial aimed at treating skin disorders linked to epidermal growth factor receptor (EGFR) inhibitor therapy. The company has selected three clinical sites in St. Louis, Miami, and Houston for the trial, which will also include a follow-up Phase 2b safety and efficacy study. The EGFR inhibitors are essential for treating several cancers, including non-small cell lung cancer and breast cancer. CEO Robb Knie emphasized that this selection marks a significant milestone for Hoth as they prepare to begin enrollment.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced the completion of a private placement, raising $10 million in gross proceeds. The company sold 2,000,000 shares of common stock and warrants to purchase up to 2,500,000 shares at $5.00 each. The proceeds will support the development of product candidates and general corporate purposes. The warrants have an exercise price of $5.00 and a term of 5.5 years. Hoth is also required to file a registration statement with the SEC within 15 days for the resale of the securities.